Heparin-Induced Thrombocytopenia

Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-up

(2009) Anna Vittoria Mattioli et al.   AMERICAN HEART JOURNAL

Studies of the immune response in heparin-induced thrombocytopenia

(2009) T. E. Warkentin et al.   BLOOD

False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus

(2009) R. PAUZNER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia

(2009) T. BAKCHOUL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital

(2009) Makiko Ban-Hoefen et al.   THROMBOSIS RESEARCH

Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy

(2008) Gustavo B. F. Oliveira   ARCHIVES OF INTERNAL MEDICINE

Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion

(2008) Z. Xiao et al.   BLOOD

Treatment and Prevention of Heparin-Induced Thrombocytopenia

(2008) Theodore E. Warkentin et al.   CHEST

Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays

(2008) T. E. WARKENTIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes

(2008) K. KRAUEL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events

(2008) Marco Guerrini et al.   NATURE BIOTECHNOLOGY

Outbreak of Adverse Reactions Associated with Contaminated Heparin

(2008) David B. Blossom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System

(2008) Takashi Kei Kishimoto et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients with Heparin-Induced Thrombocytopenia

(2008) Tyree H Kiser et al.   PHARMACOTHERAPY

Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings

(2008) A. Greinacher et al.   THROMBOSIS RESEARCH